Whether chronic dosing may also lead to improved basal glucose levels, which had been observed in glucagon receptor-deficient, STZ-treated T1DM mice (6) and after 14 days of anti-glucagon antibody treatment in diabetic ob/ob mice (41), will be the subject of further investigation. This evidence concerns the gene GCG and type 1 diabetes mellitus.